MindWalk (NASDAQ:HYFT) Trading 5.8% Higher - Time to Buy?

Key Points

• MindWalk shares rose 5.8% on Friday, trading as high as $1.29 on volume of 244,976 shares, above its average session volume.
• Analysts remain mixed but generally constructive: the stock carries a “Moderate Buy” consensus rating and a $5.00 average target price, though one firm still rates it a sell.
• The company recently missed quarterly earnings estimates, posting a loss of $0.06 per share on $3.0 million in revenue, while analysts expect a full-year loss of $0.23 per share.

MindWalk Holdings Corp. (NASDAQ:HYFT - Get Free Report)'s share price traded up 5.8% on Friday . The company traded as high as $1.29 and last traded at $1.27. 244,976 shares changed hands during mid-day trading, an increase of 45% from the average session volume of 168,838 shares. The stock had previously closed at $1.20.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HYFT shares. UBS Group reaffirmed a "buy" rating on shares of MindWalk in a report on Friday, March 13th. Weiss Ratings started coverage on shares of MindWalk in a report on Wednesday, January 14th. They set a "sell (d-)" rating for the company. Zacks Research raised shares of MindWalk from a "strong sell" rating to a "hold" rating in a report on Monday, February 16th. HC Wainwright reaffirmed a "buy" rating on shares of MindWalk in a report on Friday, March 13th. Finally, JonesTrading started coverage on shares of MindWalk in a report on Thursday, April 16th. They set a "buy" rating and a $5.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

MindWalk Stock Performance

The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.64 and a current ratio of 3.74. The company has a market cap of $58.62 million, a PE ratio of -6.35 and a beta of 0.65. The business's 50-day moving average price is $1.19.

MindWalk (NASDAQ:HYFT - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.50 million. MindWalk had a negative net margin of 66.79% and a negative return on equity of 69.37%. Equities research analysts expect that MindWalk Holdings Corp. will post -0.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MindWalk

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd increased its position in MindWalk by 118.6% in the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company's stock valued at $149,000 after acquiring an additional 44,331 shares in the last quarter. Jane Street Group LLC increased its position in MindWalk by 147.3% in the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company's stock valued at $293,000 after acquiring an additional 96,018 shares in the last quarter. Renaissance Technologies LLC increased its position in MindWalk by 8.4% in the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company's stock valued at $435,000 after acquiring an additional 18,600 shares in the last quarter. Bank of Montreal Can increased its position in MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company's stock valued at $100,000 after acquiring an additional 24,500 shares in the last quarter. Finally, Bridgeway Capital Management LLC acquired a new stake in MindWalk in the 4th quarter valued at about $91,000. Institutional investors and hedge funds own 6.70% of the company's stock.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.